镭-223 联合阿比特龙治疗的前列腺癌患者发生脆性骨折的风险更高：泼尼松可能是罪魁祸首。
Higher Risk of Fragility Fractures in Prostate Cancer Patients Treated with Combined Radium-223 and Abiraterone: Prednisone May Be the Culprit.
机构信息
Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Spedali Civili Hospital, Brescia, Italy.
Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Spedali Civili Hospital, Brescia, Italy.
出版信息
Eur Urol. 2019 Jun;75(6):894-895. doi: 10.1016/j.eururo.2019.01.026. Epub 2019 Jan 31.
Results from the ERA 223 trial of abiraterone combined with radium-223 among men with chemotherapy-naïve castration-resistant prostate cancer and bone metastases show no improvement in survival free from symptomatic skeletal events. We hypothesize that this finding might be attributable to bone loss induced by the concomitantly administered prednisone.
来自 abiraterone 联合镭-223 治疗化疗初治去势抵抗性前列腺癌伴骨转移男性的 ERA 223 试验结果显示，无进展生存和无症状骨骼事件方面没有改善。我们假设这一发现可能归因于同时给予的泼尼松引起的骨丢失。
Zotero 插件